34642-38-1Relevant academic research and scientific papers
Synthesis of carbon-14 labelled (5Z)-4-bromo-5-(bromomethylene)-2(5H)- furanone: A potent quorum sensing inhibitor
Persson, Tobias,Johansen, Steen K.,Martiny, Lars,Givskov, Michael,Nielsen, John
, p. 627 - 634 (2004)
The potent quorum sensing inhibitor (5Z)-4-bromo-5-(bromomethylene)-2(5H)- [2-14C]furanone has been prepared in five steps in 7.7% overall yield starting from bromo[1-14C]acetic acid. Condensation of ethyl bromo[1-14C]acetate with ethyl acetoacetate followed by decarboxylation was accelerated by microwave heating to afford [1- 14C]levulinic acid. Subsequently, bromination and oxidation gave the targeted furan-2-one with a radiochemical purity of > 97% and a specific activity of 57 mCi/mmol. Copyright
Synthesis and spectroscopic characterization of [1′-14C]ubiquinone-2, [1′-14C]-5-demethoxy-5-hydroxyubiquinone-2, and [1′-14C]-5-demethoxyubiquinone-2
Van Der Klei, Anita,De Jong, Robertus L. P.,Lugtenburg, Johan,Tielens, Aloysius G. M.
, p. 3015 - 3023 (2007/10/03)
[1′-14C]Ubiquinone-2, [1′-14C]-5-demethoxy-5-hydroxyubiquinone-2, and [1′-14C]-5-demethoxyubiquinone-2 have been synthesised from [1-14C]acetic acid. A common feature of these benzoquinones is the isoprenoid chain, and the 14C-label has therefore been incorporated in this isoprenoid. The coupling of the different quinone head groups and the isoprenoid chain is the last step in the total synthesis, to prevent unnecessary loss of the labelled material during synthesis. The products have been characterised by mass spectrometry, 1H NMR and 13C NMR.
Pharmacokinetics of the new antihypertensive agent nipradilol in rats. 1st communication: Metabolism and disposal after single oral administration of [14C]nipradilol
Kabuto,Kimata,Yonemitsu,Koide,Nakao,Suzuki
, p. 1674 - 1679 (2007/10/02)
The metabolism and disposal of a new antihypertensive and antianginal agent, 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H- 1-benzopyran (nipradilol, K-351) were studied using its [14C]-labelled compound in rats. The plasma level of radioactivity reached the maximum 1 h after oral administration, and the majority of radioactivities administered were recovered in urine and via the bile in feces within 48 h. From the foregoing it is obvious that the drug was absorbed from the gastrointestinal tract rapidly and well, and was eliminated from the body completely. The unchanged drug detected in the plasma and urine after oral administration of 30 mg/kg was more than 10 times as much as that after 3 mg/kg. This fact indicates that the first-pass metabolism of the drug has been saturated. Denitronipradilol, 4- and 5-hydroxynipradilol, and 4- and 5-hydroxydenitronipradilol were identified as major metabolites in the plasma and excreta, and the degradation compounds of the aminohydroxypropoxy side chain were also found as minor metabolites. Among these metabolites, 4-hydroxy metabolites were found mainly as unconjugates and 5-hydroxy metabolites as glucuronides. These findings suggest that the possible metabolic pathways of nipradilol in rats involve reductive denitration of the nitroxy group, hydroxylation at the benzopyran skeleton, oxidative degradation of the β-blocking side chain and their glucuronidation.
